BIORESTORATIVE THERAPIES INC (BRTX) Stock Fundamental Analysis

NASDAQ:BRTX • US0906556065

0.2185 USD
-0.05 (-18.47%)
At close: Feb 20, 2026
0.205 USD
-0.01 (-6.18%)
After Hours: 2/20/2026, 8:19:46 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall BRTX gets a fundamental rating of 3 out of 10. We evaluated BRTX against 521 industry peers in the Biotechnology industry. BRTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, BRTX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • BRTX had negative earnings in the past year.
  • BRTX had a negative operating cash flow in the past year.
  • In the past 5 years BRTX always reported negative net income.
  • BRTX had a negative operating cash flow in each of the past 5 years.
BRTX Yearly Net Income VS EBIT VS OCF VS FCFBRTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

  • The Return On Assets of BRTX (-224.55%) is worse than 89.64% of its industry peers.
  • Looking at the Return On Equity, with a value of -574.11%, BRTX is doing worse than 76.01% of the companies in the same industry.
Industry RankSector Rank
ROA -224.55%
ROE -574.11%
ROIC N/A
ROA(3y)-89.42%
ROA(5y)-144.93%
ROE(3y)-108.73%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BRTX Yearly ROA, ROE, ROICBRTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

  • BRTX has a better Gross Margin (93.35%) than 94.63% of its industry peers.
  • The Profit Margin and Operating Margin are not available for BRTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.35%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BRTX Yearly Profit, Operating, Gross MarginsBRTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • BRTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, BRTX has more shares outstanding
  • The number of shares outstanding for BRTX has been increased compared to 5 years ago.
  • BRTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BRTX Yearly Shares OutstandingBRTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
BRTX Yearly Total Debt VS Total AssetsBRTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

  • Based on the Altman-Z score of -49.10, we must say that BRTX is in the distress zone and has some risk of bankruptcy.
  • BRTX's Altman-Z score of -49.10 is on the low side compared to the rest of the industry. BRTX is outperformed by 90.40% of its industry peers.
  • BRTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -49.1
ROIC/WACCN/A
WACC8.72%
BRTX Yearly LT Debt VS Equity VS FCFBRTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

  • BRTX has a Current Ratio of 1.37. This is a normal value and indicates that BRTX is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.37, BRTX is doing worse than 81.96% of the companies in the same industry.
  • BRTX has a Quick Ratio of 1.37. This is a normal value and indicates that BRTX is financially healthy and should not expect problems in meeting its short term obligations.
  • BRTX has a Quick ratio of 1.37. This is amonst the worse of the industry: BRTX underperforms 80.61% of its industry peers.
Industry RankSector Rank
Current Ratio 1.37
Quick Ratio 1.37
BRTX Yearly Current Assets VS Current LiabilitesBRTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • BRTX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.17%.
  • The Revenue has been growing slightly by 1.70% in the past year.
  • Measured over the past years, BRTX shows a very strong growth in Revenue. The Revenue has been growing by 25.27% on average per year.
EPS 1Y (TTM)4.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-146.27%
Revenue 1Y (TTM)1.7%
Revenue growth 3Y100.17%
Revenue growth 5Y25.27%
Sales Q2Q%-94.87%

3.2 Future

  • The Earnings Per Share is expected to grow by 53.21% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 210.88% on average over the next years. This is a very strong growth
EPS Next Y-42.84%
EPS Next 2Y0.05%
EPS Next 3Y39.19%
EPS Next 5Y53.21%
Revenue Next Year0.12%
Revenue Next 2Y54.95%
Revenue Next 3Y286.04%
Revenue Next 5Y210.88%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BRTX Yearly Revenue VS EstimatesBRTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
BRTX Yearly EPS VS EstimatesBRTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • BRTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BRTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BRTX Price Earnings VS Forward Price EarningsBRTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BRTX Per share dataBRTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as BRTX's earnings are expected to grow with 39.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.05%
EPS Next 3Y39.19%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for BRTX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIORESTORATIVE THERAPIES INC

NASDAQ:BRTX (2/20/2026, 8:19:46 PM)

After market: 0.205 -0.01 (-6.18%)

0.2185

-0.05 (-18.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-25
Inst Owners9.37%
Inst Owner Change10.05%
Ins Owners22.35%
Ins Owner Change0%
Market Cap1.94M
Revenue(TTM)383.40K
Net Income(TTM)-12.67M
Analysts82.5
Price Target13.26 (5968.65%)
Short Float %1.92%
Short Ratio0.1
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.37%
Min EPS beat(2)10.13%
Max EPS beat(2)22.6%
EPS beat(4)3
Avg EPS beat(4)-7.91%
Min EPS beat(4)-93.06%
Max EPS beat(4)28.7%
EPS beat(8)7
Avg EPS beat(8)13.38%
EPS beat(12)10
Avg EPS beat(12)12.44%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-55.04%
Min Revenue beat(2)-97.44%
Max Revenue beat(2)-12.63%
Revenue beat(4)0
Avg Revenue beat(4)-73.67%
Min Revenue beat(4)-97.44%
Max Revenue beat(4)-12.63%
Revenue beat(8)3
Avg Revenue beat(8)38.19%
Revenue beat(12)6
Avg Revenue beat(12)44.41%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)62.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-22.95%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.16%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-42.31%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-36.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.06
P/FCF N/A
P/OCF N/A
P/B 0.88
P/tB 1.18
EV/EBITDA N/A
EPS(TTM)-1.47
EYN/A
EPS(NY)-1.16
Fwd EYN/A
FCF(TTM)-1.21
FCFYN/A
OCF(TTM)-1.21
OCFYN/A
SpS0.04
BVpS0.25
TBVpS0.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -224.55%
ROE -574.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.35%
FCFM N/A
ROA(3y)-89.42%
ROA(5y)-144.93%
ROE(3y)-108.73%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 23.51%
Cap/Sales 12.73%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.37
Quick Ratio 1.37
Altman-Z -49.1
F-Score3
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)175.34%
Cap/Depr(5y)N/A
Cap/Sales(3y)170.15%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-146.27%
EPS Next Y-42.84%
EPS Next 2Y0.05%
EPS Next 3Y39.19%
EPS Next 5Y53.21%
Revenue 1Y (TTM)1.7%
Revenue growth 3Y100.17%
Revenue growth 5Y25.27%
Sales Q2Q%-94.87%
Revenue Next Year0.12%
Revenue Next 2Y54.95%
Revenue Next 3Y286.04%
Revenue Next 5Y210.88%
EBIT growth 1Y-20.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-64.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-72.1%
OCF growth 3YN/A
OCF growth 5YN/A

BIORESTORATIVE THERAPIES INC / BRTX FAQ

Can you provide the ChartMill fundamental rating for BIORESTORATIVE THERAPIES INC?

ChartMill assigns a fundamental rating of 3 / 10 to BRTX.


What is the valuation status of BIORESTORATIVE THERAPIES INC (BRTX) stock?

ChartMill assigns a valuation rating of 1 / 10 to BIORESTORATIVE THERAPIES INC (BRTX). This can be considered as Overvalued.


What is the profitability of BRTX stock?

BIORESTORATIVE THERAPIES INC (BRTX) has a profitability rating of 1 / 10.